TY - JOUR
T1 - Clinical trials of hydroxyurea in patients with cancer and leukemia
AU - Fishbein, William N.
AU - Carbone, Paul P.
AU - Freireich, Emil J.
AU - Misra, Dwijendra
AU - Frei, Emil
PY - 1964
Y1 - 1964
N2 - Hydroxyurea (HU) was studied in 53 patients with malignant disease. Toxicity at the tolerated dose of 25 to 50 mg. per kilogram (0.75 to 1.5 Gm. per square meter) was mainly myelosuppression and was rapidly reversible upon drug withdrawal. HU or its metabolites interfere with normal as well as leukemic hemopoietic cells. HU can produce beneficial effects in chronic myelogenous leukemia (CML) as manifested by a fall in white blood count, decrease in hepatosplenomegaly, improvement in anemia and M/E ratio, In patients with acute leukemia, HU regularly causes a decrease in leukemic cells, but rarely induces remission. No significant antitumor activity was seen in the 13 patients with nonleukemic neoplasms. From this study, it is suggested that the drug has potential application in the treatment of CML and for the rapid lowering of the high white blood cell count of patients with blastic crisis and acute leukemia. Studies pertaining to the mode of action of the drug are briefly reviewed.
AB - Hydroxyurea (HU) was studied in 53 patients with malignant disease. Toxicity at the tolerated dose of 25 to 50 mg. per kilogram (0.75 to 1.5 Gm. per square meter) was mainly myelosuppression and was rapidly reversible upon drug withdrawal. HU or its metabolites interfere with normal as well as leukemic hemopoietic cells. HU can produce beneficial effects in chronic myelogenous leukemia (CML) as manifested by a fall in white blood count, decrease in hepatosplenomegaly, improvement in anemia and M/E ratio, In patients with acute leukemia, HU regularly causes a decrease in leukemic cells, but rarely induces remission. No significant antitumor activity was seen in the 13 patients with nonleukemic neoplasms. From this study, it is suggested that the drug has potential application in the treatment of CML and for the rapid lowering of the high white blood cell count of patients with blastic crisis and acute leukemia. Studies pertaining to the mode of action of the drug are briefly reviewed.
UR - http://www.scopus.com/inward/record.url?scp=0012031754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0012031754&partnerID=8YFLogxK
U2 - 10.1002/cpt196455574
DO - 10.1002/cpt196455574
M3 - Article
C2 - 14209774
AN - SCOPUS:0012031754
SN - 0009-9236
VL - 5
SP - 574
EP - 580
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 5
ER -